Hologic INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
HOLX
Hologic INCHologic, Inc. filed a definitive additional proxy statement to address stockholder lawsuits regarding its merger disclosures and announced a voluntary recall of its Brevera Breast Biopsy System needles.
HOLX
Hologic INCHologic, Inc. provides employees with an FAQ detailing the impact of its pending acquisition by Blackstone and TPG on unvested RSUs, stock options, and ESPP, along with general company operations post-merger.
HOLX
Hologic INCHologic, Inc. stockholders are invited to a special meeting on February 5, 2026, to vote on a merger agreement with affiliates of Blackstone and TPG, offering $76.00 cash plus a CVR up to $3.00 per share.
HOLX
Hologic INCHologic, Inc. issued an internal FAQ to employees detailing the impact of its acquisition by Blackstone and TPG on benefits, bonuses, and equity awards.
HOLX
Hologic INCHologic, Inc. announced its unanimous board-approved acquisition by Blackstone and TPG, aiming to accelerate growth as a private company.
HOLX
Hologic INCHologic, Inc. announced robust fiscal fourth-quarter results with significant revenue and EPS growth, alongside a definitive agreement to be acquired by Blackstone and TPG for up to $79 per share.
HOLX
Hologic INCHologic, Inc. announces its agreement to be acquired by private equity firms Blackstone and TPG, shifting from public to private ownership with a focus on long-term strategic growth.
HOLX
Hologic INCHologic, a women's health technology company, has agreed to be acquired by investment firms Blackstone and TPG for up to $79 per share, valuing the company at over $18 billion.
HOLX
Hologic INCHologic, Inc. announced an agreement to be acquired by Blackstone and TPG for up to $79 per share, aiming for accelerated growth and global expansion.
HOLX
Hologic INCHologic, Inc. announced an agreement to be acquired by Blackstone and TPG for up to $79 per share, valuing the company at up to $18.3 billion.
HOLX
Hologic INCHologic, a global leader in women's health, has agreed to be acquired by funds managed by Blackstone and TPG for up to $79 per share, including a contingent value right.
HOLX
Hologic INCHologic, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
HOLX
Hologic INCHologic delivered solid fiscal year 2024 results, achieving revenue growth in core businesses and demonstrating strong profitability and cash flow.